XESM
MLC
Market cap163mUSD
Jun 18, Last price
7.25EUR
1D
-0.68%
1Q
-5.84%
Jan 2017
-40.57%
IPO
-34.39%
Name
Malin Corporation PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-16.17%
Rev. gr., 5y
8.79%
Revenues
0k
Net income
0k
CFO
-1m
L-59.38%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Malin Corporation plc operates as a life sciences firm across Ireland and the United States, primarily through its various subsidiaries. The company specializes in developing and delivering vital solutions for critical medical challenges. Its portfolio includes groundbreaking cell and gene therapies aimed at patients with significant unmet medical requirements. Furthermore, Malin provides treatments targeting pressing needs in oncology, infectious diseases, and autoimmune conditions. It also addresses specific women's health concerns, such as recurrent vulvovaginal candidiasis, and offers remedies for fungal nail infections like onychomycosis. Beyond these, Malin's offerings extend to pharmaceutical products for protein misfolding disorders, a sophisticated platform designed to identify pathogenic bacteria within the gut microbiome, and advanced UV-light disinfection technologies. Additionally, it offers corporate secretarial services. Established in 2014, Malin Corporation plc maintains its headquarters in Dublin, Ireland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||